Open AccessA Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection
Author(s) -
Richard B. Moss,
Carrie Hansen,
Robert Sanders,
S B Hawley,
T. Li,
Roy T. Steigbigel
Publication year - 2012
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jis622
Subject(s) - placebo , viral load , medicine , clinical trial , viral shedding , pandemic , influenza a virus , virology , immunology , virus , covid-19 , infectious disease (medical specialty) , pathology , alternative medicine , disease
DAS181, a novel host-directed antiviral in development for influenza treatment, was assessed in this phase II clinical trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom